查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884070

甲型肝炎疫苗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Hepatitis A Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 196 Pages | 商品交期: 请询问到货日

价格

甲型肝炎疫苗市场成长驱动因素

由于甲型肝炎疾病流行率上升、疫苗接种计划扩大以及政府主导的旨在预防甲型肝炎感染的举措增加，全球甲型肝炎疫苗市场正经历显着增长。根据本报告，预计该市场规模将在 2024 年达到 12.4 亿美元，并在 2025 年增长至 12.6 亿美元。预计到 2032 年，该市场规模将显着成长至 25.7 亿美元，在预测期内实现 10.7% 的强劲复合年增长率。北美地区凭藉其先进的医疗保健体系和广泛的疫苗接种覆盖率，在 2024 年保持了其领先地位，市场占有率达到 50%。

甲型肝炎是一种病毒性肝臟感染，主要透过受污染的食物和水或密切接触传播。症状包括发烧、噁心、腹部不适，严重时可出现黄疸和急性肝衰竭。由于卫生条件差、个人卫生习惯不良以及清洁用水匮乏，这种感染在低收入和中等收入地区尤其常见。由于接种疫苗是最有效的预防措施，全球对甲型肝炎疫苗的需求持续成长。葛兰素史克（GSK plc）、赛诺菲（Sanofi）、默克（Merck & Co.）和科兴生物（Sinovac）等主要公司提供全球认可的疫苗，并致力于提高疫苗接种率。

市场驱动因素

甲型肝炎病例呈上升趋势

全球甲型肝炎病例的不断增加推动了疫苗接种工作。卫生条件差、水源受污染和个人卫生习惯不良仍是主要的风险因素。例如，乌兹别克在2024年的前两个月报告了9507例儿童甲型肝炎感染病例，凸显了在高风险地区开展疫苗接种计划的紧迫性。

各国政府加强疫苗接种计画

世界各国政府正在扩大国家疫苗接种计划，以预防疫情爆发并最大限度地降低医疗成本。在欧盟/欧洲经济区，2022年报告了4548例病例，促使当局加强疫苗接种策略。

市场限制

疫苗价格高且取得途径有限

甲型肝炎疫苗的生产需要冷链物流和严格的监管合规，这推高了整体成本。这限制了低收入国家的取得途径。在墨西哥，单剂疫苗的价格为935.7美元，而完成免疫需要两剂，这使得许多人难以负担疫苗。疫苗价格可承受性方面的差距持续阻碍着全球根除甲型肝炎的努力。

市场机会

新兴市场的本土疫苗研发

印度和中国等国家正在投资本土疫苗研发，以减少对进口的依赖。 2024年1月，印度免疫公司（Indo Immunologicals）推出了印度首款国产甲型肝炎疫苗Havisure，显着提高了疫苗的可及性和可负担性。预计到2032年，此类本土创新将创造巨大的市场机会。

市场挑战

冷链效率低

甲型肝炎疫苗必须储存在2°C至8°C之间。许多低收入地区缺乏足够的冷链基础设施，促使疫苗浪费和免疫接种率低。这些限制仍然是市场扩张的主要障碍。

市场趋势

旅行疫苗需求成长

随着全球旅行的增加，旅行者对甲型肝炎疫苗的需求显着增长。高收入国家的旅行诊所和药房报告称，他们会主动为前往甲型肝炎流行地区的旅客接种疫苗。例如，韩国强烈建议在前往风险地区之前至少接种一剂疫苗。

细分市场概览

按类型

由于全球批准和广泛供应，灭活疫苗细分市场在2024年占主导地位。 2023年，中国生物技术有限公司（SINOVAC）的灭活疫苗 "Healive" 在吉尔吉斯斯坦获得监管部门批准。虽然活疫苗有效，但其市场仍集中在印度和中国。

依年龄组

由于成熟的疫苗接种方案，儿童区隔市场引领市场。美国疾病管制与预防中心 (CDC) 建议所有 12 至 23 个月大的婴儿进行常规疫苗接种。

依剂型划分

由于易于接种，液体疫苗（例如默克公司的 Vaqta 和葛兰素史克公司的 Havrix）占了大部分市场占有率。冻干粉剂疫苗因其更长的保存期限和储存优势仍然十分重要。

依通路划分

在 2024 年，政府采购机构在大规模采购项目的推动下，占了市场主导地位。 2025 年，全球疫苗免疫联盟 (GAVI) 承诺投入 2.5 亿美元，用于改善低收入国家的疫苗可及性。

区域展望

北美 - 2024 年 6.2 亿美元

北美在全球市场中处于领先地位，这得益于其较高的疫苗接种覆盖率和不断上升的疾病发病率。光是在美国，2016 年至 2020 年间就记录了 44,660 起疫情，推动了疫苗需求。

亚太地区

这是第二大市场，也是预期复合年增长率最高的地区。例如，预计印度在 2024 年上半年将报告超过 6,000 例病例，这将推动疫苗的快速普及。

欧洲

强而有力的政府主导的疫苗接种计划和近期疫苗推广措施正在促进稳步增长。

拉丁美洲、中东/非洲

儘管市场占有率较低，但不断提高的公众意识和有针对性的健康宣传活动正在推动疫苗的逐步普及。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家和地区甲型肝炎流行情况（2024 年）
  • 主要公司产品线分析
  • 市场技术进步
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）

第五章：全球甲型肝炎疫苗市场分析、洞察与预测 (2019-2032)

  • 按类型划分的市场分析、洞察与预测
    • 灭活​​疫苗
    • 减毒活疫苗
    • 其他
  • 按年龄组别划分的市场分析、洞察与预测
    • 儿童
    • 成人
  • 按剂型划分的市场分析、洞察与预测
    • 溶液
    • 冻干粉
  • 依分销管道划分的市场分析、洞察与预测
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 按地区划分的市场分析、洞察与预测
    • 北部美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美甲型肝炎疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲甲型肝炎疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章 亚太地区甲型肝炎疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲甲型肝炎疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲甲型肝炎疫苗市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • 葛兰素史克 (GSK plc)
    • 赛诺菲 (Sanofi)
    • 默克公司 (Merck & Co., Inc.)
    • 沃克哈特 (Wockhardt)
    • 印度免疫学有限公司 (Indian Immunologicals Ltd (IIL))
    • 中国生物技术有限公司 (SINOVAC)
    • Vaxines Trading, Inc.
    • 宝灵生物製药株式会社 (Boryung Biopharma Co.)
Product Code: FBI113584

Growth Factors of hepatitis A vaccines Market

The global hepatitis A vaccines market is witnessing strong growth due to rising disease prevalence, expanding immunization programs, and increasing government initiatives aimed at preventing hepatitis A infections. According to the report, the market size reached USD 1.24 billion in 2024, is expected to grow to USD 1.26 billion in 2025, and is projected to rise significantly to USD 2.57 billion by 2032, registering a robust CAGR of 10.7% during the forecast period. With a 50% market share in 2024, North America remained the dominant region, reflecting advanced healthcare systems and strong adoption of immunization practices.

Hepatitis A is a viral liver infection transmitted primarily through contaminated food and water or via close personal contact. Symptoms range from fever, nausea, and abdominal discomfort to jaundice and acute liver failure. The infection is particularly prevalent in low- and middle-income regions due to insufficient sanitation, poor hygiene, and restricted access to clean water. As vaccination is the most effective preventive measure, demand for hepatitis A vaccines continues to grow worldwide. Leading companies such as GSK plc, Sanofi, Merck & Co., Inc., and SINOVAC offer globally approved vaccines, contributing to increasing immunization coverage.

Market Drivers

Growing Prevalence of Hepatitis A

Rising hepatitis A cases globally are driving vaccine uptake. Poor sanitation, contaminated water sources, and limited hygiene practices continue to be major risk factors. In Uzbekistan, for example, 9,507 hepatitis A infections among children were reported in the first two months of 2024, highlighting the urgent need for vaccination programs in high-risk regions.

Increased Government Immunization Initiatives

Governments worldwide are expanding national vaccination programs to prevent outbreaks and minimize healthcare expenditures. In the EU/EEA, 4,548 cases were reported in 2022, prompting authorities to reinforce vaccination strategies.

Market Restraints

High Vaccine Costs and Limited Access

Production of hepatitis A vaccines requires cold-chain logistics and stringent regulatory compliance, elevating overall costs. This restricts access in low-income countries. In Mexico, the cost per dose is USD 935.7, and full immunization requires two doses-making the vaccine unaffordable for many. This affordability gap continues to hinder global eradication efforts.

Market Opportunities

Indigenous Vaccine Development in Emerging Markets

Countries such as India and China are investing in domestic vaccine development to reduce reliance on imports. In January 2024, Indian Immunologicals Ltd launched Havisure, India's first indigenously developed hepatitis A vaccine, significantly improving accessibility and affordability. Such regional innovations are expected to create substantial market opportunities through 2032.

Market Challenges

Cold-Chain Inefficiencies

Hepatitis A vaccines must be stored between 2°C and 8°C. Many lower-income regions lack adequate cold-chain infrastructure, resulting in vaccine wastage and reduced immunization coverage. These limitations remain a key barrier to market expansion.

Market Trends

Rising Demand for Traveler Immunization

With global travel increasing, the demand for hepatitis A vaccination among travelers has grown significantly. Travel clinics and pharmacies in high-income countries report strong vaccine uptake as travelers visit hepatitis A-endemic nations. South Korea, for example, strongly recommends at least one dose before travel to at-risk regions.

Segmentation Overview

By Type

The inactivated vaccine segment dominated the market in 2024 due to global approvals and wide availability. In 2023, SINOVAC's inactivated vaccine Healive gained regulatory approval in Kyrgyzstan. Live attenuated vaccines, though effective, remain regionally concentrated in India and China.

By Age Group

The pediatric segment led the market due to established vaccination protocols. The U.S. CDC recommends routine vaccination for all children aged 12-23 months.

By Form

Solution-based vaccines such as Vaqta (Merck) and Havrix (GSK) hold the majority share due to ease of administration. Lyophilized powders remain important for extended shelf life and storage benefits.

By Distribution Channel

Government suppliers dominated in 2024, driven by large-scale procurement programs. In 2025, GAVI allocated USD 250 million to enhance vaccine access in low-income countries.

Regional Outlook

North America - USD 0.62 Billion in 2024

North America led the global market, supported by high vaccination rates and rising disease incidence. The U.S. alone recorded 44,660 outbreak cases between 2016 and 2020, fueling vaccine demand.

Asia Pacific

Second-largest market with the highest projected CAGR. India, for instance, reported over 6,000 cases in the first half of 2024, prompting rapid vaccine adoption.

Europe

Strong government immunization programs and recent vaccine initiatives contribute to steady growth.

Latin America & Middle East/Africa

Despite lower market shares, rising awareness and targeted health campaigns support gradual adoption.

Conclusion

With the market valued at USD 1.24 billion in 2024, expected to reach USD 1.26 billion in 2025, and projected to attain USD 2.57 billion by 2032, the global hepatitis A vaccines market is positioned for substantial long-term expansion. Increasing disease burden, rising vaccination initiatives, and new indigenous vaccine developments will collectively drive growth throughout the forecast period.

Segmentation By Type

  • Inactivated
  • Live Attenuated
  • Others

By Age Group

  • Pediatric
  • Adults

By Form

  • Solution
  • Lyophilized Powder

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Age Group, Dose, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Age Group, Dose, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Hepatitis A - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Technological Advancements in Market
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Age Group
    • 5.2.1. Pediatric
    • 5.2.2. Adolts
  • 5.3. Market Analysis, Insights and Forecast - By Form
    • 5.3.1. Solution
    • 5.3.2. Lyophilized Powder
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Age Group
    • 6.2.1. Pediatric
    • 6.2.2. Adolts
  • 6.3. Market Analysis, Insights and Forecast - By Form
    • 6.3.1. Solution
    • 6.3.2. Lyophilized Powder
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. S.
    • 6.5.2. Canada

7. Europe Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Age Group
    • 7.2.1. Pediatric
    • 7.2.2. Adolts
  • 7.3. Market Analysis, Insights and Forecast - By Form
    • 7.3.1. Solution
    • 7.3.2. Lyophilized Powder
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Age Group
    • 8.2.1. Pediatric
    • 8.2.2. Adolts
  • 8.3. Market Analysis, Insights and Forecast - By Form
    • 8.3.1. Solution
    • 8.3.2. Lyophilized Powder
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Age Group
    • 9.2.1. Pediatric
    • 9.2.2. Adolts
  • 9.3. Market Analysis, Insights and Forecast - By Form
    • 9.3.1. Solution
    • 9.3.2. Lyophilized Powder
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Hepatitis A Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Age Group
    • 10.2.1. Pediatric
    • 10.2.2. Adolts
  • 10.3. Market Analysis, Insights and Forecast - By Form
    • 10.3.1. Solution
    • 10.3.2. Lyophilized Powder
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Wockhardt
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Indian Immunologicals Ltd (IIL)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. SINOVAC
      • 11.2.6.1. Overview
        • 11.2.6.1.1. Products & services
        • 11.2.6.1.2. SWOT Analysis
        • 11.2.6.1.3. Recent Developments
        • 11.2.6.1.4. Strategies
        • 11.2.6.1.5. Financials (Based on Availability)
    • 11.2.7. Vaxines Trading, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Boryung Biopharma Co.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2033
  • Table 3: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2034
  • Table 4: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 5: Global Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 6: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 7: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 8: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 9: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 10: North America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 12: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 13: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 14: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 15: Europe Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 17: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 18: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 19: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 22: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 23: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 24: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 25: Latin America Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 27: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 28: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Form, 2019-2032
  • Table 29: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Hepatitis A Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Figure 1: Global Hepatitis A Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Hepatitis A Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 4: Global Hepatitis A Vaccines Market Value Share (%), by Form 2024 & 2032
  • Figure 5: Global Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 6: Global Hepatitis A Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 7: North America Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 8: North America Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 9: North America Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 10: North America Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 11: North America Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 12: North America Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 13: North America Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 14: North America Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 15: North America Hepatitis A Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Hepatitis A Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 18: Europe Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 19: Europe Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 20: Europe Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 21: Europe Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 22: Europe Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 23: Europe Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 24: Europe Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 25: Europe Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 28: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 29: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 30: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 31: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 32: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 33: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 35: Asia Pacific Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 38: Latin America Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 39: Latin America Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 40: Latin America Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 41: Latin America Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 42: Latin America Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 43: Latin America Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 45: Latin America Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 48: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Type, 2024
  • Figure 49: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 50: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 51: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Form, 2024 & 2032
  • Figure 52: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Form, 2024
  • Figure 53: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 55: Middle East & Africa Hepatitis A Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Hepatitis A Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Hepatitis A Vaccines Market Share (%), By Company, 2024